Net loss for the three months ended September 30, 2024, was $23.2 million or $0.30 per basic and diluted share, compared to a net loss of $15.8 million ... enhancing drug exposure over an extended ...
The improvement is due to expense savings of $3.5 million, partially offset by a total revenue decline of $3.4 million that is primarily attributable to the Company exiting its shared mail program and ...